Spots Global Cancer Trial Database for recurrent follicular lymphoma

Every month we try and update this database with for recurrent follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma	NCT02652910	Recurrent Adult... Recurrent Folli... Recurrent Mantl... Stage III Adult... Stage III Folli... Stage III Mantl... Stage IV Adult ... Stage IV Follic... Stage IV Mantle...	CD19.CAR-T cell...	18 Years - 70 Years	Xinqiao Hospital of Chongqing
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma	NCT05152459	Recurrent Folli... Refractory Foll...	Tazemetostat Ublituximab Umbralisib	18 Years -	City of Hope Medical Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma	NCT02438501	Recurrent Folli...	Low-dose involv... Involved-field ...	18 Years - 65 Years	Wuhan University
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	NCT03401853	Recurrent Diffu... Recurrent Folli... Refractory Diff... Refractory Foll...	Laboratory Biom... Pembrolizumab Rituximab Obinutuzumab	18 Years -	University of Washington
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma	NCT04156828	Grade 3b Follic... Recurrent Diffu... Recurrent Folli... Refractory Diff... Non-Hodgkin's L...	Copanlisib Gemcitabine Carboplatin Dexamethasone Rituximab Pegfilgrastim	18 Years -	University of Washington
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma	NCT01644799	Recurrent Folli...	idelalisib lenalidomide	18 Years -	Alliance for Clinical Trials in Oncology
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	NCT03579927	CD19 Positive Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Refractory B-Ce... Refractory Diff... Refractory Foll...	Autologous Hema... Carmustine Cytarabine Etoposide Filgrastim Melphalan Rituximab Umbilical Cord ...	18 Years - 70 Years	M.D. Anderson Cancer Center
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	NCT03035331	Aggressive Non-... Indolent Non-Ho... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Prima... Recurrent T-Cel... Small Lymphocyt...	Cryosurgery Dendritic Cell ... Laboratory Biom... Pembrolizumab Pneumococcal 13... Quality-of-Life...	18 Years -	Mayo Clinic
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma	NCT02438501	Recurrent Folli...	Low-dose involv... Involved-field ...	18 Years - 65 Years	Wuhan University
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	NCT02797470	HIV Infection Mature T-Cell a... Plasmablastic L... Recurrent Adult... Recurrent Adult... Recurrent Burki... Recurrent Folli... Stage III Folli... Stage III Mantl... Stage IV Follic... Stage IV Mantle...	Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Lentivirus Vect... Melphalan Peripheral Bloo...	18 Years -	AIDS Malignancy Consortium
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	NCT01076543	AIDS-Related Ho... Recurrent Adult... Recurrent Folli... Recurrent Lymph... Recurrent Margi... Recurrent Non-H... Recurrent T-Cel... Waldenstrom Mac...	Laboratory Biom... Lenalidomide Temsirolimus	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	NCT01995669	Grade 3a Follic... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Foll... Refractory Marg... Refractory Smal...	Laboratory Biom... Lenalidomide Obinutuzumab	18 Years -	M.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	NCT03598998	Anaplastic Larg... Nodal Periphera... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Matur... Recurrent Monom... Recurrent Mycos... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Matu... Refractory Myco... Refractory Peri... Subcutaneous Pa...	Pembrolizumab Pralatrexate	18 Years -	City of Hope Medical Center
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	NCT03277729	Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent...	Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho...	18 Years -	Fred Hutchinson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma	NCT04156828	Grade 3b Follic... Recurrent Diffu... Recurrent Folli... Refractory Diff... Non-Hodgkin's L...	Copanlisib Gemcitabine Carboplatin Dexamethasone Rituximab Pegfilgrastim	18 Years -	University of Washington
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	NCT06343376	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Mantl... Recurrent Trans... Recurrent Trans... Refractory Chro... Refractory Diff... Refractory Foll... Refractory High... Refractory Mant... Refractory Tran... Refractory Tran...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... EGFRt/19-28z/IL... Fludarabine Pho... Leukapheresis Multigated Acqu... Positron Emissi...	18 Years -	Roswell Park Cancer Institute
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	NCT00309842	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra...	- 55 Years	Masonic Cancer Center, University of Minnesota
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	NCT03147885	Diffuse Large B... Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Indol... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Mant... Stage III Non-H... Stage IV Non-Ho... Transformed Rec...	Selinexor	18 Years -	Barbara Ann Karmanos Cancer Institute
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	NCT04578600	Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal...	Lenalidomide Obinutuzumab Oral Azacitidin...	18 Years -	University of California, Davis
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma	NCT02438501	Recurrent Folli...	Low-dose involv... Involved-field ...	18 Years - 65 Years	Wuhan University
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	NCT02927964	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L...	Ibrutinib Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: